WHO sees “potentially positive data” in coronavirus treatment



[ad_1]

The World Health Organization said Tuesday that some treatments appear to be limiting the severity or duration of Covid-19 disease and that it was focusing on learning more about four or five of the most promising.

The Geneva-based WHO is leading a global initiative to develop safe and effective vaccines, tests and drugs to prevent, diagnose and treat Covid-19. Respiratory disease has infected 4.19 million people worldwide, according to a Reuters count.

“We have some treatments that appear to be in very early studies that limit the severity or duration of the disease, but we have nothing that can kill or stop the virus,” spokeswoman Margaret Harris said in a briefing, referring to the disease. Body. called Solidarity Trial of drugs against the disease.

“We have potentially positive data, but we need to see more data to be 100 percent sure we can tell this treatment on that one,” he added, saying more research was needed and that it was planned.

Mrs. Harris did not mention the treatments. Gilead Science Inc says its antiviral medication remdesivir has helped improve outcomes for patients with Covid-19.

Clinical data published last month on remdesivir raised hopes that it could be an effective treatment. Several studies looking at combinations of antiviral drugs have also suggested that they can help patients fight the virus.

Results from a Hong Kong trial published this month showed that a triple combination of antiviral drugs helped relieve symptoms in patients with mild or moderate Covid-19 infection and quickly reduced the amount of virus in their bodies.

The trial, which involved 127 patients, compared those who received the combination drug, consisting of the HIV drug lopinavir-ritonavir, the hepatitis drug ribavirin, and treatment of multiple sclerosis interferon beta, with a control group that received only the HIV medicine.

A treatment of malaria advocated by United States President Donald Trump as a “game changer” in the fight against coronavirus again failed to show benefit in hospitalized patients with Covid-19, according to a study this month.

Although the study had certain limitations, physicians reported that the use of hydroxycolloquine did not decrease the need for patients requiring respiratory assistance or the risk of death.

Vaccine

In Geneva, the WHO official issued a cautionary note about expectations for a vaccine, saying that coronaviruses in general are “very difficult viruses” that are “difficult to produce vaccines.”

[ad_2]